Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

Visualizza tutta la documentazione

E4876

Sigma-Aldrich

17α-Ethynylestradiol

≥98%

Sinonimo/i:

Ethinylestradiol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C20H24O2
Numero CAS:
57-63-6
Peso molecolare:
296.40
Beilstein:
2419975
Numero CE:
200-342-2
Numero MDL:
MFCD00003690
Codice UNSPSC:
12352200
ID PubChem:
24894585
NACRES:
NA.77

Origine biologica

synthetic

Sterilità

non-sterile

Saggio

≥98%

Stato

powder

Punto di fusione

182-183 °C (lit.)

Solubilità

ethanol: 50 mg/mL, clear, colorless to faintly yellow

Condizioni di spedizione

ambient

Temperatura di conservazione

room temp

Stringa SMILE

[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)C#C)[C@]1([H])CCc4cc(O)ccc24

InChI

1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1
BFPYWIDHMRZLRN-SLHNCBLASA-N

Informazioni sul gene

human ... ESR1(2099)
rat ... Afp(24177) , Esr1(24890) , Shbg(24775)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

17α-Ethynylestradiol (EE2) is a synthetic hormone. It is a derivative of estradiol (E2). It is implicated in estrogen replacement therapy and suspension of breastfeeding. EE2 is used to treat osteoporosis, menopausal and postmenopausal syndrome. It is also used to treat prostatic cancer and breast cancer in postmenopausal women. EE2 functions as an endocrine-disrupting chemical (EDC).

Applicazioni

17α-Ethynylestradiol has been used to study the effect of exogenous estrogen and selective estrogen receptor modulator (SERM) in rats. It also has been used to increase the concentration of low density lipoprotein (LDL) receptor in rabbit liver.

Azioni biochim/fisiol

17α-Ethynylestradiol is an orally bio-active synthetic estrogen used as an oral contraceptive.

Avvertenze

Danger

Indicazioni di pericolo

H302,H351,H360Fd,H410

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Repr. 1A

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Dispositivi di protezione individuale

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
WXBD4408V
WXBD3601V
WXBC9894V
WXBC9372V
WXBC9012V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

α-Estradiol powder, ≥98% (TLC)

Sigma-Aldrich

E8750

α-Estradiol

17α-Ethynylestradiol 3-cyclopentyl ether

Sigma-Aldrich

E7887

17α-Ethynylestradiol 3-cyclopentyl ether

Estriol ≥97%

Sigma-Aldrich

E1253

Estriol

Ethinylestradiol for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001124

Ethinylestradiol for system suitability

19-Norethindrone ≥98%, powder

Sigma-Aldrich

N4128

19-Norethindrone

Dienogest ≥98% (HPLC)

Sigma-Aldrich

SML1468

Dienogest

Levonorgestrel Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1850

Levonorgestrel

Huda Omar Ali et al.
PloS one, 11(3), e0152114-e0152114 (2016-03-22)
Oestrogens influence the pathology and development of hormone-sensitive breast cancers. Tissue factor pathway inhibitor (TFPI) has been shown to be associated with breast cancer pathogenesis. Recently, we found TFPI mRNA levels to be significantly reduced by oestrogens in a breast
Richard Mark Evans et al.
PloS one, 7(8), e43606-e43606 (2012-08-23)
A growing body of experimental evidence indicates that the in vitro effects of mixtures of estrogenic chemicals can be well predicted from the estrogenicity of their components by the concentration addition (CA) concept. However, some studies have observed small deviations
Admane H Shanthanagouda et al.
PloS one, 9(2), e88165-e88165 (2014-02-14)
In human, a reduction in estrogen has been proposed as one of the key contributing factors for postmenopausal osteoporosis. Rodents are conventional models for studying postmenopausal osteoporosis, but the major limitation is that ovariectomy is needed to mimic the estrogen
Analysis of 17-beta-estradiol and 17-alpha-ethinylestradiol in biological and environmental matrices?a review
Barreiros L, et al.
Microchemical Journal, Devoted to the Application of Microtechniques in All Branches of Science, 126, 243-262 (2016)
Anders E A Dahm et al.
BMC cardiovascular disorders, 6, 40-40 (2006-10-13)
Hormone therapy, oral contraceptives, and tamoxifen increase the risk of thrombotic disease. These compounds also reduce plasma content of tissue factor pathway inhibitor-1 (TFPI), which is the physiological inhibitor of the tissue factor pathway of coagulation. The current aim was
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.